Hi Mr Cod,
I thought that exact same thing and questioned Jon on this on 16/08. See my question below and his reply in capitals.
3- In relation to the ROW rights deal for Trof is the possible sale of the company at a later date a consideration when looking at who to partner with? I’d imagine it would be a little more difficult to find a potential acquirer if all the trof rights are sold. AS YOU KNOW I BELIEVE NNZ-2591 GLOBAL RIGHTS AND IN PARTICULAR US RIGHTS ARE THE MOST VALUABLE ASSET AND MUCH MORE ATTRACTIVE TO POTENTIAL ACQUIRERS THAN TROFINETIDE EX-US RIGHTS. HAVING SAID THAT WE ARE OF COURSE MINDFUL ABOUT THE FUTURE AS WELL AS THE PRESENT WHEN CONSIDERING OUR OPTIONS FOR ROW.
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-12
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |